Skip to main content

Table 3 Physiological end points by treatment group

From: The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients

Outcome PMX-HP group Non-PMX-HP group
Baseline (n = 29) Day 3 (n = 26) P value within groupa Baseline (n = 30) Day 3 (n = 20) P value within groupb P value between groups on day 3c P value between group change from baseline and day 3d
Primary outcome
 mHLA-DR expression (%), median (Q1, Q3) 33.4 (27.4–40.7) 39.2 (27.1–45.8) 0.025 e 30 (15.8–36.6) 30.7 (19.5–36.8) 0.13 0.027 (0.042) e 0.027 (0.11)e
 mHLA-DR expression (MFI), mean (SD) 481.4 (131.5) 509.0 (139.9) 0.78 446.6 (142.1) 447.3 (148.9) 0.35 0.16 (0.035)e 0.34 (0.038)e
Secondary outcomes
 CD11b (%), mean (SD) 15.4 (9) 13.7 (9.5) 0.30 14.3 (10.5) 16.2 (10.1) 0.001 0.39 (0.15)e 0.002 (0.001) e
 CD-11b (MFI), mean (SD) 189.7 (57.1) 165.4 (53.1) 0.045 186.2 (53.3) 223.5 (48.0) < 0.001 0.001 (< 0.001) e < 0.001 (< 0.001) e
 Neutrophil chemotaxis (%), mean (SD) 42.8 (12.5) 47.9 (10.2) 0.030 42.3 (13.7) 46.2 (12.3) 0.74 0.60 (0.77)e 0.07 (0.08)e
 Presepsin (pg/ml), median (Q1, Q3) 5514 (4088, 10,513) 2895 (2190, 6038) 0.059 5030 (2459, 10,734) 3468 (2204, 6038) 0.12 0.93 0.38
 CVS SOFA score, median (Q1, Q3) 4 (4, 4) 3 (0, 4) 0.003 4 (4, 4) 3 (1, 4) 0.26 0.71 0.16
 Inotropic score, median (Q1, Q3) 36 (6.6, 70) 11 (1, 49.2) 0.13 30 (2, 83) 14 (0, 36) 0.94 0.57 0.20
 Vasopressor dependency index (mmHg−1), median (Q1, Q3) 0.4 (0.1, 1.1) 0.1 (0.01, 0.7) 0.14 0.4 (0.1, 1.1) 0.2 (0, 0.6) 0.96 0.60 0.25
 Noradrenaline (μg/kg/min), median (Q1, Q3) 0.2 (0.0, 0.4) 0.01 (0, 0.2) 0.23 0.3 (0.0, 0.4) 0.1 (0, 0.4) 0.85 0.42 0.42
 EAA level, median (Q1, Q3) 0.8 (0.7, 1) 0.7 (0.6, 0.9) 0.11 0.7 (0.7, 0.9) 0.6 (0.5, 0.9) 0.14 0.84 0.90
  1. Data represent median (25th percentile, 75th percentile) unless otherwise noted
  2. PMX-HP polymyxin B hemoperfusion, mHLA-DR monocyte human leukocyte antigen, Q1 25th percentile, Q3 75th percentile, MFI mean fluorescence intensity, SD standard deviation, CVS SOFA cardiovascular Sequential Organ Failure Assessment, EAA endotoxin activity assay, Italic data represent P value statistically significant
  3. aP value for comparison between day 1 and day 3 within PMX-HP group using Student’s t test or Kruskal–Wallis test
  4. bP value for comparison between day 1 and day 3 within non-PMX-HP group using Student’s t test or Kruskal–Wallis test
  5. cP value for comparison between PMX-HP and non-PMX-HP groups on day 3 using Student’s t test or Kruskal–Wallis test
  6. dP value for comparing groups on mean or median change between day 3 and day 1 using Student’s t test or Kruskal–Wallis test
  7. eAdjusted for renal replacement therapy status